利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.026 秒)

    Transparent polyimide-polyester compositions, method of manufacture, and articles thereof
    1.
    发明授权
    Transparent polyimide-polyester compositions, method of manufacture, and articles thereof 有权
    透明聚酰亚胺 - 聚酯组合物，制造方法及其制品

    公开(公告)号：US08546516B2

    公开(公告)日：2013-10-01

    申请号：US12815754

    申请日：2010-06-15

    申请人： Robert R. Gallucci ,  Mark A. Sanner

    发明人： Robert R. Gallucci ,  Mark A. Sanner

    IPC分类号： C08G63/127

    CPC分类号： C08L67/02 ,  C08G73/1046 ,  C08G73/1053 ,  C08G73/1067 ,  C08G73/1071 ,  C08K5/005 ,  C08K5/0066 ,  C08L79/08 ,  C08L2666/20

    摘要： A thermoplastic polymer composition comprises a combination of: 40 to 60 pbw, of a polyetherimides, polyetherimide sulfones, or combination thereof having a weight average molecular weight from 5,000 to 80,000 Daltons; 40 to 60 pbw of a polyethylene terephthalate, the polyethylene terephthalate having a diethylene glycol content from 0.1 to 4 wt %, based on the weight of the polyethylene terephthalate, an intrinsic viscosity that is more than 0 and less than 0.83 dl/g, and carboxylic acid end groups in an amount from 10 to 150 meq/Kg; from 0 pbw to 1 pbw, based on 100 pbw of the polymer composition of a stabilizer selected from phenol-containing stabilizers, phosphorus-containing stabilizers, or a combination thereof; and, based on the weight of the polyethylene terephthalate, 10 to 300 antimony; 0 to 300 ppm of cobalt; and 0 to 300 ppm of titanium; wherein the polymer composition is bisphenol A free.

    摘要翻译： 热塑性聚合物组合物包含以下组合：40至60pbw的重均分子量为5,000至80,000道尔顿的聚醚酰亚胺，聚醚酰亚胺砜或其组合; 40〜60pbw的聚对苯二甲酸乙二醇酯，基于聚对苯二甲酸乙二醇酯的重量，二甘醇含量为0.1〜4重量％的聚对苯二甲酸乙二醇酯，特性粘度大于0且小于0.83dl / g，以及 羧酸端基的量为10至150meq / Kg; 从0pbw至1pbw，基于100pbw的聚合物组合物选自含苯酚的稳定剂，含磷稳定剂或其组合的稳定剂; 并且基于聚对苯二甲酸乙二醇酯的重量为10〜300个锑; 0〜300ppm的钴; 和0〜300ppm的钛; 其中聚合物组合物是双酚A游离的。

    Sterilized polyetherimide articles
    5.
    发明授权
    Sterilized polyetherimide articles 有权
    无菌聚醚酰亚胺制品

    公开(公告)号：US08497004B2

    公开(公告)日：2013-07-30

    申请号：US13486435

    申请日：2012-06-01

    申请人： Scott Michael Davis ,  Robert R. Gallucci ,  Shawn Lee ,  Mark A. Sanner

    发明人： Scott Michael Davis ,  Robert R. Gallucci ,  Shawn Lee ,  Mark A. Sanner

    IPC分类号： B29D22/00

    CPC分类号： C08J7/123 ,  A61L2/14 ,  A61L2/208 ,  A61L2202/24 ,  C08J2379/08 ,  Y10T428/13 ,  Y10T428/1352 ,  Y10T428/24479

    摘要： A sterilized article comprising a sterilized or hydrogen peroxide vapor-sterilized polymer composition, the polymer composition comprising a polyetherimide, wherein after exposure to 100 cycles of the hydrogen peroxide plasma sterilization using a mixture of hydrogen peroxide vapor and hydrogen peroxide plasma for 30 minutes at 20 to 55° C., the color of the polymer composition of the article exhibits a color shift of delta E of 10 units or less relative to the color of the polymer composition color before the first hydrogen peroxide plasma sterilization cycle, wherein delta E is measured in accordance with ASTM D2244.

    摘要翻译： 包含灭菌或过氧化氢蒸气灭菌的聚合物组合物的灭菌制品，所述聚合物组合物包含聚醚酰亚胺，其中在使用过氧化氢蒸汽和过氧化氢等离子体的混合物暴露于100个循环的过氧化氢等离子体灭菌之后，在20℃ 至55℃，制品的聚合物组合物的颜色相对于第一过氧化氢等离子体灭菌循环前的聚合物组合物颜色的颜色显示为10单位或更小的ΔE的色移，其中测量ΔE 根据ASTM D2244。

    HYDROSTABLE POLYETHERIMIDE BLENDS, METHODS OF MANUFACTURE, AND ARTICLES FORMED THEREFROM
    7.
    发明申请
    HYDROSTABLE POLYETHERIMIDE BLENDS, METHODS OF MANUFACTURE, AND ARTICLES FORMED THEREFROM 有权
    可水解的聚己内酯混合物，制造方法和形成的制品

    公开(公告)号：US20120029125A1

    公开(公告)日：2012-02-02

    申请号：US13020897

    申请日：2011-02-04

    申请人： Robert Russell GALLUCCI ,  Mark A. SANNER ,  Georgios S. ZAFIRIS

    发明人： Robert Russell GALLUCCI ,  Mark A. SANNER ,  Georgios S. ZAFIRIS

    IPC分类号： C08K5/526 ,  B29C49/00 ,  B29C45/00 ,  C08K5/05 ,  C08L79/08

    CPC分类号： C08L69/005 ,  C08G73/1046 ,  C08G73/1071 ,  C08K3/26 ,  C08K3/346 ,  C08K5/13 ,  C08K5/49 ,  C08L69/00 ,  C08L79/08 ,  C08L2666/20

    摘要： A composition comprising, based on the total weight of the composition, from 10 to 90 wt. % of a polyetherimide with a weight average molecular weight from 10,000 to 80,000 Daltons; from 10 to 90 wt. % of a polymer selected from polycarbonates, polyester-polycarbonates, polyalkylene terephthalates, or a combination thereof, from 0.005 to 1 wt. % of a hydrotalcite having a particle size of less than 10 micrometer and a magnesium oxide to aluminum oxide mole ratio of 1.0 to 5.0; from 0.01 to 1.0 wt. % of a phosphorus-containing stabilizer; from 0.01 to 1.00 wt. % of a hindered phenol stabilizer; optionally, from 0 to 3 wt. % of a polyolefin; and optionally, from 0 to 5 wt. % of an inorganic metal oxide.

    摘要翻译： 一种组合物，其包含基于组合物的总重量为10至90wt。 ％的重均分子量为10,000至80,000道尔顿的聚醚酰亚胺; 10至90wt。 选自聚碳酸酯，聚酯 - 聚碳酸酯，聚对苯二甲酸亚烷基酯或其组合的聚合物的百分比为0.005-1wt。 ％的粒径小于10微米的水滑石和氧化镁与氧化铝的摩尔比为1.0-5.0; 0.01〜1.0重量％ ％的含磷稳定剂; 0.01至1.00wt。 ％的受阻酚稳定剂; 任选地，0至3重量％ ％的聚烯烃; 和任选地0至5wt。 ％的无机金属氧化物。

    Thiazole derivatives
    8.
    发明授权
    Thiazole derivatives 失效
    噻唑衍生物

    公开(公告)号：US06720427B2

    公开(公告)日：2004-04-13

    申请号：US10144403

    申请日：2002-05-13

    申请人： Mark A. Sanner ,  Chris J. Helal ,  Christopher B. Cooper

    发明人： Mark A. Sanner ,  Chris J. Helal ,  Christopher B. Cooper

    IPC分类号： C07D21722

    CPC分类号： C07D277/62 ,  C07D277/42 ,  C07D277/46 ,  C07D277/48 ,  C07D277/64 ,  C07D417/12 ,  C07D417/14

    摘要： The invention provides compounds of formula 1 wherein R1, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission are described. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.

    摘要翻译： 本发明提供了式1化合物，其中R 1，R 3和R 4如上定义，及其药学上可接受的盐。 式1的化合物表示具有抑制cdk5，cdk2和GSK-3的活性。 描述了包含式1化合物的药物组合物和方法，用于治疗包括异常细胞生长如癌症和神经变性疾病和病症以及受多巴胺神经传递影响的疾病和病症。 还描述了包含用于治疗雄性生育力和精子活力的式1化合物的药物组合物和方法; 糖尿病 葡萄糖耐量降低; 代谢综合征或综合征X; 多囊卵巢综合征; 脂肪生成和肥胖; 造血和虚弱，例如年龄相关的身体表现下降; 急性肌肉减少症，例如与烧伤，卧床休息，肢体固定或主要胸部，腹部和/或整形外科手术相关的肌肉萎缩和/或恶病质; 败血症 脱发，脱发，秃头; 和免疫缺陷。

    2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
    9.
    发明授权
    2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors 失效
    2,7-取代的八氢-1H-吡啶并[1,2-A]吡嗪衍生物作为血清素受体的配体

    公开(公告)号：US06231833B1

    公开(公告)日：2001-05-15

    申请号：US09368984

    申请日：1999-08-05

    申请人： Kishor A. Desai ,  Anton F. J. Fliri ,  Mark A. Sanner

    发明人： Kishor A. Desai ,  Anton F. J. Fliri ,  Mark A. Sanner

    IPC分类号： A61K4900

    CPC分类号： C07D471/04 ,  A61K31/4985

    摘要： Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Ar1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO2, CHOH, C═O, or —(CR3R4); and n is 0-2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems:

    摘要翻译： 通式I的取代的吡啶并[1,2-a]吡嗪; 其中Ar和Ar 1表示各种碳环和杂环芳环; A表示O，S，SO，SO 2，CHOH，C = O或 - （CR 3 R 4）; 和n是0-2，以及其前体是体内多巴胺受体亚型和5-羟色胺（5HT）的配体，因此可用于治疗多巴胺和血清素系统的紊乱：